AstraZeneca Stock - Thursday chart view and consensus snapshot
18.06.2026 - 21:56:03 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 21:53 UTC. Details in the imprint.
AstraZeneca (GB0009895292) is one of Europe's largest pharmaceutical groups with a dual listing in London and on Nasdaq. With no new market-moving company announcement on Thursday, attention shifts to the chart picture and analyst consensus on the stock, according to recent market data.
All news and data on AstraZeneca stock
Further background, corporate releases and archive price data on AstraZeneca are available via the ad hoc news topic page and the company’s investor-relations site.
How AstraZeneca shares trade on Thursday
Across major venues, AstraZeneca shares remain actively traded but without a fresh corporate catalyst on Thursday. On the London Stock Exchange, the stock recently changed hands at about GBP 131.48, according to market data compiled earlier in the day.
In the US, AstraZeneca is listed under the AZN ticker on Nasdaq, where the last available official close was $177.89 on 06/17/2026, with a market capitalization around $551.78 billion based on that price level. These levels frame the current technical picture into which new information would be priced.
Chart and technical picture for AZN
From a chart perspective, AstraZeneca remains a heavyweight component in global health-care indices, and the stock’s recent trading range reflects that status. Short-term fluctuations have been relatively contained, with no outsized move reported on Thursday relative to broader European pharma peers.
Technical analysts typically watch moving averages and support zones for a stock of this size, but no major technical breakout or breakdown has been flagged in the latest commentary. Against this backdrop, incremental news on the company’s pipeline or regulatory milestones could quickly shift the technical narrative.
Analyst sentiment and consensus ratings
Analyst sentiment toward AstraZeneca remains broadly constructive. Across several data providers, the stock continues to carry a consensus rating in the Buy range, underlining confidence in the company’s late-stage pipeline and earnings trajectory, as highlighted in recent coverage.
For example, compiled analyst data show a Buy consensus and an average long-term price target that sits meaningfully above the current Nasdaq quote, implying further upside based on these models. These figures, however, vary by provider and are regularly updated as new trial results, earnings and regulatory decisions emerge.
The business and key products behind the stock
AstraZeneca generates revenue primarily from prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare diseases. Flagship products include blockbuster cancer therapy Tagrisso and cardiovascular drug Farxiga, both of which remain central to the group’s growth profile.
Where the stock trades today
AstraZeneca shares (GB0009895292) trade on the London Stock Exchange at around GBP 131.48 and on Nasdaq at about $177.89 as of 06/18/2026, 16:05 UTC.
Key facts on AstraZeneca stock
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- WKN: 886455
- Ticker: AZN
- Venue: London Stock Exchange / Nasdaq
- Price (as of 06/18/2026, 16:05 UTC): 131.48 GBP / 177.89 USD
- Market cap: 551.78 billion USD (as of 06/17/2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: FTSE 100, key global health-care indices
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
